For patients managing congestive heart failure with medications but still experiencing declining function, stem cell therapy is an emerging area of research. This article explores what the science suggests, who may be a candidate, and what a physician-guided protocol looks like at Cellular Institute in Cancún.

Muse cells and iPSCs are both pluripotent, but Muse cells occur naturally in the body and don't require genetic reprogramming or carry tumor risk, while iPSCs are built in a lab from adult cells and come with a real risk of forming teratomas. This guide breaks down the biology, the clinical trial data behind each, and what the difference actually means if you're weighing regenerative treatment options.

Both exosome therapy and stem cell therapy are advanced regenerative tools, but they work differently and may be better suited for different conditions. This guide helps patients understand the key biological differences, what each approach may support, and how to make an informed decision with physician guidance.